Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Postdoctoral Fellowship, Immunobiology, Yale University School of Medicine 1992 - 1994
  • Medical Oncology Fellowship, Yale University School of Medicine 1991 - 1994
  • Internal Medicine Residency, Yale University School of Medicine 1989 - 1991
  • M.D., University of Connecticut, School of Medicine 1989
  • Ph.D., University of Connecticut, School of Medicine 1987
• 

  Previous Appointments & Affiliations

  • Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2019 - 2020
• Recognition
• 

  In the News

  • OCT 25, 2022

    School of Medicine

    A New Generation of Tools To Fight Cancer
• Research
• 

  Selected Grants

  • Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy awarded by National Institutes of Health 2022 - 2027
  • Duke Center for Advancement of Child Health (CAtCH). awarded by National Institutes of Health 2021 - 2026
  • Nektar PROPEL awarded by Nektar Therapeutics 2020 - 2025
  • Investigating the Role of a Novel Dendritic Cell Subset within Sentinel Lymph Node Tissues in Immune Evasion and Melanomagenesis awarded by Department of Defense 2021 - 2024
  • Clinical Biomarker Study of the Tumor NLRP3 Inflammasome and its Role in Anti-PD-1 Immunotherapy Resistance awarded by Conquer Cancer Foundation 2021 - 2024
  • Anti-PD1 in combination with an inhibitor of PCSK9 to increase MHC class I molecule expression on tumor cells as immunotherapy for NSCLC awarded by Department of Defense 2021 - 2024
  • Discovering Novel Tumor-Reactive Antibodies in Pembrolizumab-Treated NSCLC awarded by Lung Cancer Initiative of North Carolina 2023
  • Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance awarded by H. Lee Moffitt Cancer Center & Research Institute 2019 - 2023
  • Use of an oncolytic adenovirus to promote anti-tumor T-cell responses in ovarian cancer awarded by Foundation for Women's Cancer 2022 - 2023
  • T32 UNC - Duke Immunotherapy Training Program awarded by University of North Carolina - Chapel Hill 2021 - 2022
  • Evaluating the Impact of PCSK9 on the Composition of the Tumor-Immune Microenvironment and Treatment Response to Immune Checkpoint Blockade in NSCLC awarded by Lung Cancer Initiative of North Carolina 2021 - 2022
  • Identifying Epigenetic Biomarkers that Predict Response to Immunotherapy in Lung Cancer Patients awarded by Lung Cancer Initiative of North Carolina 2020 - 2022
  • Anonymous Donation awarded by Anonymous Trust 2020 - 2022
  • Targeting Immunosuppressive Cancer Associated Fibroblasts and Immune Checkpoints in NSCLC awarded by H. Lee Moffitt Cancer Center & Research Institute 2019 - 2022
  • Tumor Infiltrating lymphocyte adoptive T cell therapy for NSCLC awarded by H. Lee Moffitt Cancer Center & Research Institute 2019 - 2021
  • CA191146: Long-acting PEG-like conjugates of an immune checkpoint inhibitor and a selective cytokine for combination immunotherapy awarded by United States Army Medical Research Acquisition Activity 2020 - 2021
  • A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF THE COMBINATION OF NKTR-214 AND NIVOLUMAB OR THE COMBINATION OF NKTR-214, NIVOLUMAB, AND OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES awarded by Nektar Therapeutics 2019 - 2020
• 

  External Relationships

  • Achilles Therapeutics
  • Glympse Bio
  • Guardian Bio
  • Immutep
  • Memgen
  • RAPT Biotherapeutics
  • Shoreline
  • Tubulis
  • Xilis
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Scherpereel, Arnaud, Scott Antonia, Yolanda Bautista, Francesco Grossi, Dariusz Kowalski, Gérard Zalcman, Anna K. Nowak, et al. “First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.” Lung Cancer 167 (May 2022): 8–16. https://doi.org/10.1016/j.lungcan.2022.03.012.
       Full Text  Link to Item
    • Antonia, Scott J., Hossein Borghaei, Suresh S. Ramalingam, Leora Horn, Javier De Castro Carpeño, Adam Pluzanski, Marco A. Burgio, et al. “Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.” Lancet Oncol 20, no. 10 (October 2019): 1395–1408. https://doi.org/10.1016/S1470-2045(19)30407-3.
       Full Text  Link to Item
    • Antonia, Scott J. “Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.” N Engl J Med 380, no. 10 (March 7, 2019): 990. https://doi.org/10.1056/NEJMc1900407.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.